Dermatology groups across New York are losing substantial revenue due to Mohs modifier misuse, biopsy bundling failures, and payer-specific authorization denials.
MBC maps each dermatology CPT to LCD compliance thresholds before submission and tracks provider-level Net Collection Ratio so leadership sees measurable EBITDA impact.
If Mohs revenue fluctuates monthly, documentation precision and payer intelligence gaps are the cause.
Call 888-357-3226 or Contact Us: https://bit.ly/4tLlfro
#NewYorkDermatology #DermatologyBillingUSA #MohsSurgery #HealthcareEBITDA #RevenueIntegrity